These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 32217372

  • 1. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 2. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saji H.
    Bioorg Med Chem; 2016 May 15; 24(10):2251-6. PubMed ID: 27073053
    [Abstract] [Full Text] [Related]

  • 3. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 15; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and Radiolabeling of Glu-Urea-Lys with 99mTc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor.
    Hatamabadi D, Joukar S, Shakeri P, Balalaie S, Yazdani A, Khoramjouy M, Mazidi SM, Kobarfard F, Mosayebnia M, Bozorgchami N, Ahmadi M, Ayyoubzadeh SM, Shahhosseini S.
    Cancer Biother Radiopharm; 2023 Sep 15; 38(7):486-496. PubMed ID: 37578479
    [Abstract] [Full Text] [Related]

  • 5. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 15; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 6. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
    Xiao D, Duan X, Gan Q, Zhang X, Zhang J.
    Molecules; 2020 Nov 26; 25(23):. PubMed ID: 33256058
    [Abstract] [Full Text] [Related]

  • 7. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 26; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.
    Lu K, Zhang C, Zhang Z, Kuo HT, Colpo N, Bénard F, Lin KS.
    Molecules; 2023 Jun 29; 28(13):. PubMed ID: 37446782
    [Abstract] [Full Text] [Related]

  • 9. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug 29; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 10. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y, Ando M, Watanabe H, Ono M.
    Ann Nucl Med; 2024 Oct 29; 38(10):847-851. PubMed ID: 38976087
    [Abstract] [Full Text] [Related]

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Oct 29; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 12. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).
    Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, Rosenström U, Tolmachev V, Orlova A.
    Int J Mol Sci; 2023 Dec 12; 24(24):. PubMed ID: 38139219
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 12; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 14. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.
    J Med Chem; 2013 Aug 08; 56(15):6108-21. PubMed ID: 23799782
    [Abstract] [Full Text] [Related]

  • 15. Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression.
    Wang Y, Shao G, Wu J, Cui C, Zang S, Qiu F, Jia R, Wang Z, Wang F.
    Contrast Media Mol Imaging; 2018 Aug 08; 2018():8046541. PubMed ID: 29853810
    [Abstract] [Full Text] [Related]

  • 16. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT, Lin KS, Zhang Z, Zhang C, Merkens H, Tan R, Roxin A, Uribe CF, Bénard F.
    Theranostics; 2022 Aug 08; 12(14):6179-6188. PubMed ID: 36168623
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of a New 99mTc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection.
    Farahani AM, Maleki F, Sadeghzadeh N, Abediankenari S, Abedi SM, Erfani M.
    Anticancer Agents Med Chem; 2020 Aug 08; 20(14):1695-1703. PubMed ID: 32560611
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
    Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ.
    Sci Rep; 2020 Mar 06; 10(1):4179. PubMed ID: 32144340
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.
    Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.
    Eur J Nucl Med Mol Imaging; 2017 Apr 06; 44(4):647-661. PubMed ID: 27847991
    [Abstract] [Full Text] [Related]

  • 20. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM.
    Eur J Nucl Med Mol Imaging; 2013 Apr 06; 40(4):486-95. PubMed ID: 23179945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.